Citations

Clear

9383 citation(s) found for "Thomas, PS".

Physician Perceptions and Clinical Outcomes of a Novel Standardized Outside Hospital Admission Process
Gallagher, Kennedy E., Riggio, Jeffrey M., Kubey, Alan A., RIGGIO, JEFFREY M. , Kubey, Alan A

Mayo Clinic

American Journal of Medical Quality | August 4, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/jmq.0000000000000339 | PMID 42549654 Get It

Transfers are high-risk events, and outside hospital admissions lack standardized processes to ensure timely delivery of essential clinical information. We piloted a novel, standardized process for outside admissions to a single academic medical center’s resident- and hospital medicine-attending-based medicine services. Following literature review, Epic UserWeb review, and frontline physician input, a workflow and templated electronic health record accept note were developed to centralize outside admission documentation. Completed by physicians during real-time communication with outside physicians, the template captures key clinical data and incorporates a communication checklist. Physician education was delivered electronically and in person. Subjective attending and resident perceptions were assessed via electronic prepost surveys administered 1 week before and 90 days after implementation. Secondarily, exploratory patient clinical outcomes were assessed through 90-day prepost manual retrospective chart review. Survey responses were obtained from 60/38 residents and 12/7 attendings (pre/post). Documentation sufficiency on patient arrival was directionally promising among residents (21.7% vs 39.5%, P = 0.062). Satisfaction with the admission process and perceived patient safety improved significantly among residents and attendings ( P ≤ 0.036). Most respondents rated the note as useful or very useful (84% residents; 86% attendings), and attendings reported reduced time managing outside admissions. The intervention was associated with exploratory, nonsignificant reductions in rapid response team activation, intensive care unit transfer, 30-day readmission, mortality, and length of stay compared with preintervention patients. A standardized documentation and communication process improved physician satisfaction and perceived patient safety, with promising exploratory patient outcomes. Further study is warranted to assess impact at scale.
Malignant B-cell States Orchestrate Spatially Organized Immune Ecosystems in B-cell Lymphomas
Mondello, Patrizia , Sadekova, Alisa , fede, ksenia, Dasari, Surendra , Au, Wesley , Kriukov, Kirill , Meerson, Mark, Novak, Joseph, Yang, Zhi-Zhang , Gysbers, Brianna J. , Villasboas, Jose, Wiebe, Daniil S. , Shvyrkova, Anastasiia, Margaryan, Sargis, Nesmelov, Alexander, Sarachakov, Aleksander, Petrosyants, Arman, Bagaev, Alexander , Novak, Anne J. , Casulo, Carla, Hsi, Eric, Fowler, Nathan, King, Rebecca, Singh, Harinder, Armand, Philippe, Pasqualucci, Laura, Ansell, Stephen M. , Binder, Moritz , Yang, Zhi-Zhang , Gysbers, Brianna J , Postovalova, Ekaterina , Wiebe, Daniil , Kotlov, Nikita , Wang, Yucai , Novak, Anne J , Habermann, Thomas , Maurer, Matthew , Cerhan, James R , Shlomchik, Mark , Ansell, Stephen M , Mondello, Patrizia , Dasari, Surendra , Au, Wesley, Binder, Moritz , Meerson, Mark , Novak, Joseph P. , Villasboas, José C. , Guzman, Emmanuel Contreras , Nesmelov, Alexander, Wang, Yucai , Habermann, Thomas M. , Hsi, Eric D. , Maurer, Matthew J. , Cerhan, James R. , Singh, Harinder, Armand, P., Pasqualucci, Laura , Burack, Richard

Mayo Clinic

No container title available | August 3, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-10435263/v1 | PMID 42620132 Get It

Abstract Germinal center (GC)-derived lymphomas arise within a specialized immune ecosystem, yet whether malignant cells direct its remodeling remains unclear. Integrating genomic, transcriptomic, spatial, and functional analyses across follicular lymphoma and diffuse large B-cell lymphoma, we define a developmental framework linking malignant B-cell differentiation state to tumor microenvironment (TME) organization. Rather than segregating by histology, lymphomas align along a shared differentiation continuum in which proliferative dark zone (DZ) states associate with immune-depleted TMEs, whereas post-GC/memory B-cell (MBC) states drive inflamed but immunosuppressed TMEs. Spatial profiling reveals collapse of GC architecture and emergence of suppressive myeloid niches along this trajectory. Single-cell lineage reconstruction uncovers a DZ-to-MBC developmental axis underlying lymphoma evolution. Genetic reprogramming in vivo demonstrates that malignant differentiation state is sufficient to instruct TME remodeling. Collectively, these findings establish malignant differentiation state as a causal determinant of immune architecture across GC-derived lymphomas and identify lineage-directed immune reprogramming as a potential therapeutic strategy.
Perioperative Factors Associated with the Conversion of Robotic-Assisted Partial Nephrectomy to Open Partial and Radical Nephrectomy
Qosja, Neda, Lee, Yeonsoo , Geldmaker, Laura, Spahiu, Matea, McCoy, Katherine , Zhang, Janie, Haehn, Daniela, Qualkenbush, Eric , Thomas, Colleen, Thiel, David D. , Kahn, Amanda E. , Qualkenbush, Eric , Thiel, David D , Geldmaker, Laura , Haehn, Daniela A. , Thomas, Colleen

Mayo Clinic

Journal of Endourology | August 1, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/08927790261473126 | PMID 42541401 Get It

Objective: To evaluate factors associated with the conversion of robotic-assisted partial nephrectomy (RAPN) to open partial nephrectomy (OPN) and radical nephrectomy (RN). Methods: We retrospectively reviewed 775 consecutive RAPNs from a single surgeon. Perioperative factors were evaluated for association with RAPN conversion such as Mayo Adhesive Probability (MAP) score, length of stay (LOS), and operative time (OT). A logistic regression model was utilized to evaluate factors associated with conversion and reported as odds ratio (OR) with 95% confidence intervals. Continuous and categorical variables were analyzed through the Wilcoxon rank-sum and chi-square tests. Results: Thirty-two (4.1%) patients had a conversion including 19 (2.5%) to OPN and 13 (1.7%) to RN. OPN conversions were related to bleeding ( n = 7), inability to dissect perinephric fat ( n = 4), liver retraction ( n = 1), and failure to secure renal hilum/progress ( n = 7). In contrast, conversions to RN were due to tumor involvement of the renal vein ( n = 3) or ureter ( n = 5) and inability to achieve negative margins ( n = 5). Patients in the conversion cohort were more likely to have larger tumor size (3.7 vs 2.8 cm; p < 0.001) and higher MAP score (3.0 vs 2.0; p = 0.04). Median LOS was higher in the conversion group (3.0 vs 2.0 days; p = 0.003). Conversions were associated with postoperative complications (28.1% vs 13.7%; p = 0.023). After adjusting tumor size in our regression model, longer OT and dissection time were statistically higher in the conversion group (OR = 2.19 [1.50–3.21]; p < 0.001 and OR = 2.67 [1.82–3.94]; p < 0.001, respectively). Conclusions: Larger tumor size and higher MAP score were associated with conversions during RAPN. Conversions were associated with higher LOS, longer OT, and postoperative complications.
Accelerating Evidence-Based Practices in Acute Kidney Injury
Brown, Jeremiah R. , Rabin, Borsika A. , Akcan‐Arikan, Ayse , Awdishu, Linda , Bagshaw, Sean M. , Brookman‐Frazee, Lauren , Cerdá, Jorge , Granado, Rolando Claure‐Del , Ghazi, Lama , Goldstein, Stuart L. , Liu, Kathleen D., Mottes, Theresa, Selby, Nicholas M. , Vijaykumar, Aarthi, Zarbock, Alexander, Neyra, Javier A. , Rewa, Oleksa G , Rabin, Borsika A , Akcan-Arikan, Ayse , Awdishu, Linda , Bagshaw, Sean M , Brookman-Frazee, Lauren , Cerdá, Jorge , Claure-Del Granado, Rolando , Ghazi, Lama , Goldstein, Stuart L , Jeong, Rachel , Kashani, Kianoush B , Koyner, Jay L , Macedo, Etienne , Pannu, Neesh , Reddy, Yuvaram N V , See, Emily , Selby, Nicholas M , Siew, Edward D , Silver, Samuel A , Srinsawat, Nattachai , Stadnick, Nicole A , Vijaykumar, Aarthi , Wald, Ron , Wilson, F Perry , Ronco, Claudio , Ostermann, Marlies , Mehta, Ravindra L , Neyra, Javier A , Kashani, Kianoush , Koyner, Jay L. , Liu, Kathleen D. , Macedo, Etienne , Mottes, Theresa , Pannu, Neesh , Reis, Thiago , Siew, Edward D. , Silver, Samuel A. , Wilson, F. Perry , Zarbock, Alexander , Ronco, Claudio , Ostermann, Marlies , Mehta, Ravindra L.

Mayo Clinic

Clinical Journal of the American Society of Nephrology | July 31, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.2215/cjn.0000001205 | PMID 42537020 Get It

Scientific evidence regarding AKI and acute kidney care has advanced in recent years. However, a knowledge gap remains on the implementation of these evidence-based practices (EBPs) into clinical care. Implementation science (IS) is focused on ensuring that this knowledge is translated in an effective, efficient and sustainable fashion. Objectives: 1) Define the current status of IS; 2) Define a roadmap for accelerating IS with a focus on patient/care partner advocacy, digital tool application, social determinants of health, and resource-limited settings; and 3) Develop a robust and broad research agenda incorporating IS methodology into the programs. Evidence Review: ADQI XXXV was conducted through a modified Delphi process with virtual meetings preceding an in-person meeting. Five workgroups were determined a priori to focus on 1) IS definitions and methods applicable to AKI and acute kidney care; 2) IS literature in AKI and acute kidney care; 3) Innovations in IS to accelerate the adoption, adherence to, and sustainment of EBPs in AKI and acute kidney care; 4) IS methods in resource-limited settings; and 5) Recommendations to identify and evaluate EBPs that are ready for implementation or de-implementation. Prior to the in-person meeting, each workgroup met virtually to review the literature and develop framework questions to address their objectives. During the two-day in person meeting, through iterative discussions, questions and supporting statements were finalized. These questions and statements were agreed upon through voting to achieve consensus, defined as agreement of ≥80%. Conclusions and Relevance: We report a structured multidisciplinary consensus for defining the role of IS in AKI and acute kidney care. Future programs should address these consensus questions and apply these statements along with IS methodology in the translation of science into clinical practice and the implementation/de-implementation of EBPs in clinical care.
Use of Digital Twins for Prediction and Practice in Nursing Education
Byrne, Matthew , Byrne, Matthew D., Byrne, Matthew D.

Mayo Clinic

Nursing Education Perspectives | July 31, 2026 | Volume: 47 | Issue: 5 | Pages: 315-315

10.1097/01.nep.0000000000001590 | PMID 42536503 Get It

Convalescent Plasma Restores Viral Clearance After Anti‐Spike Monoclonal Antibody Failure in Immunocompromised COVID‐19 Patients: A Systematic Review and Meta‐Analysis of Individual Patient Data
Focosi, Daniele , Aiello, Tommaso Francesco , Cruciani, Mario , D’Abramo, Alessandra , Marco, Patrizia De, Garcia‐Vidal, Carolina, Glingani, Claudia, Hueso, Thomas , Richier, Quentin , Tomisti, Luca , Weinbergerova, Barbora, Zani, Matteo , Zaremba, Solomiia , Cruciani, Mario , D'Abramo, Alessandra , De Marco, Patrizia , Gachoud, David , Hueso, Thomas , Joyner, Michael J , Lacombe, Karine , Mengoli, Carlo , Nicastri, Emanuele , Richier, Quentin , Rufer, Nathalie , Senefeld, Jonathon W , Sullivan, David J , Zaremba, Solomiia , Franchini, Massimo , Focosi, Daniele , Casadevall, Arturo , García‐Vidal, Carolina , Joyner, Michael J. , Mengoli, Carlo , Senefeld, Jonathon W. , Shoham, Shmuel , Sullivan, David , Weinbergerová, Barbora , Franchini, Massimo

Mayo Clinic

Reviews in Medical Virology | July 31, 2026 | Volume: 36 | Issue: 5 | Pages: No page available

10.1002/rmv.70185 | PMID 42536824 Get It

ABSTRACT Anti‐Spike monoclonal antibodies (mAbs) progressively lost efficacy during the COVID‐19 pandemic due to the emergence and predominance of resistant SARS‐CoV‐2 variants. By contrast, high‐titre COVID‐19 convalescent plasma (CCP) collected from vaccinated donors recently recovered from infection provides a polyclonal source of antibodies that remains effective in clearing SARS‐CoV‐2 in immunosuppressed patients, unable to mount an adequate immune response against the virus. We conducted a systematic review and individual participant data meta‐analysis to examine the effect of CCP in immunocompromised patients persistently positive for SARS‐CoV‐2 viraemia following mAb therapy, and to evaluate possible biological factors associated with a favourable outcome. Electronic databases were searched for studies published from January 2020 to January 2026. All studies including eligible cases were considered in the systematic review. Unpublished cases were also collected from investigators of the selected studies. The protocol was registered at PROSPERO (CRD420251142891). Forty‐seven cases (30 cases from 12 published studies and 17 unpublished cases) were included. In 33 out of 47 patients (70.2%) with a mAb‐resistant infection, SARS‐CoV‐2 clearance occurred following CCP transfusion, with a mean of 2.7 CCP units administered. In logistic regression, total CCP volume transfused was positively associated with SARS‐CoV‐2 clearance. In conclusion, CCP transfusion was associated with SARS‐CoV‐2 clearance in persistently positive immunocompromised patients following failure of anti‐Spike mAb therapy.
Immune Checkpoint Inhibitor–Associated Acute Kidney Injury
Fenoglio, Roberta , Murakami, Naoka , Sharon, Elad , Herrmann, Sandra M. , Workeneh, Biruh T., Roccatello, Dario, Blau, Jack A., Ostermann, Marlies , Ronco, Claudio , Renaghan, Amanda DeMauro , Rosner, Mitchell H. , Participants, on behalf of the ADQI Conference, Małyszko, Jolanta , Gupta, Shruti , Fenoglio, Roberta , Murakami, Naoka , Sharon, Elad , Herrmann, Sandra M , Ostermann, Marlies , Ronco, Claudio , Renaghan, Amanda DeMauro , Rosner, Mitchell H , Gupta, Shruti , Workeneh, Biruh , Roccatello, Dario , Leaf, David E.

Mayo Clinic

Journal of the American Society of Nephrology | July 31, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1681/asn.0000001232 | PMID 42536415 Get It

Immune checkpoint inhibitors (ICIs) have transformed cancer therapy but are associated with immune-related adverse events, including ICI–associated acute kidney injury (ICI-AKI). ICI-AKI presents diagnostic and management challenges and can influence decisions regarding immunosuppression and ICI rechallenge, with important implications for both kidney and cancer outcomes. An international, multidisciplinary panel convened at the 34th Acute Disease Quality Initiative (ADQI) consensus conference in September 2024. Systematic literature searches of PubMed were conducted to identify studies on the epidemiology, mechanisms, diagnosis, management, rechallenge, and outcomes of ICI-AKI. The meeting followed the established ADQI process and used a modified Delphi method to achieve consensus. Evidence was reviewed and appraised by workgroups, and consensus statements were developed through structured discussion and voting. Observational data suggest that AKI occurs in up to 20% of patients receiving ICIs, with ICI-AKI accounting for approximately 2%–5% of cases. Acute tubulointerstitial nephritis is the most common lesion, observed in 80%–90% of biopsies, although glomerular diseases are increasingly recognized. No clinical features reliably distinguish ICI-AKI from other causes of AKI, and kidney biopsy remains the diagnostic gold standard. Emerging urinary, circulating, and imaging biomarkers show promise but are not yet ready for routine clinical use. Early glucocorticoid initiation (within 3 days of ICI-AKI diagnosis versus >3 days after diagnosis) is associated with higher rates of kidney recovery, although optimal dosing and duration remain uncertain. Recurrent ICI-AKI occurs in fewer than 20% of patients undergoing ICI rechallenge. Management of high-risk populations, including kidney transplant recipients and patients with autoimmune disease or advanced CKD, requires individualized, multidisciplinary decision-making. ICI-AKI is an important and potentially reversible complication of cancer immunotherapy; these consensus statements provide a framework for diagnosis and management, support cautious ICI rechallenge in selected patients, and identify priorities for future research.
Cross-Validation of Low-Cost Potentiometric and Colorimetric Methods for Urinary Urea Quantification: Toward Accessible Monitoring of Protein Metabolism
Domínguez, R. , Yang, Valerie, Fu, Ashley, Cheng, Edward H., Terrera, Mirna, Hota, Piyush , Pradhan, Ayushi, Miranda, Sandra, Snozek, Christine, Thomas, Leslie, Lind, Mary Laura , Chen, Fang, Forzani, Erica, Dominguez, Rodrigo E , Cheng, Edward H., Miranda, Sandra, Thomas, Leslie F. , Forzani, Erica

Mayo Clinic

Analytica | July 31, 2026 | Volume: 7 | Issue: 3 | Pages: 51

10.3390/analytica7030051 Get It

Urinary urea is a key biomarker for tracking protein oxidation and nitrogen balance. A persistent analytical limitation is that conventional total-nitrogen assays do not deconvolute urinary urea from urinary ammonia, and direct measurement still requires capital-intensive clinical analyzers. Here, we implement and independently validate two cost-effective methods that resolve urinary urea by pairing the presence and absence of urease: Method 1 is a urease-coupled potentiometric assay using an ammonium ion-selective electrode (ISE method); Method 2 is a microplate Berthelot–salicylate colorimetric assay employing a repurposed consumer-grade aquarium ammonia test kit (API®) (API method). Each method was validated against the Roche Cobas C311 clinical analyzer (ISE for urinary ammonia and API for urinary urea) in healthy adult volunteers (n = 10 each), and API–ISE were then compared head-to-head for urinary urea. ISE vs. Cobas yielded R2 = 0.967, slope 95% CI [0.867, 1.173], and Bland–Altman bias of −1.02 mM (95% LoA [−7.40, +5.36] mM). API vs. Cobas yielded R2 = 0.973, slope 95% CI [0.790, 1.039], and bias of −1.55 mM (95% LoA [−11.56, +8.46] mM). API–ISE urinary urea comparison confirmed mutual agreement (R2 = 0.9976, slope 95% CI [0.946, 1.024]; bias of +3.47 mM; 95% LoA [−14.60, +21.53] mM), with mean recoveries near 100% (API: 100.7 ± 2.9%; ISE: 100.6 ± 5.4%; 20–350 mM). Both methods agreed with the clinical analyzer, supporting their potential for decentralized, resource-limited testing; clinical and point-of-care validations are needed.
Addressing financial, housing, and food insecurity to help medical trainees achieve their full potential
Nguyen, Mytien , Thomas, Larissa R. , West, Colin P. , West, C P

Mayo Clinic

Academic Medicine | July 31, 2026 | Volume: 101 | Issue: 8 | Pages: 893-897

10.1093/acamed/wvag162 | PMID 42533731 Get It

Cemiplimab and Fianlimab With Neoadjuvant Chemotherapy in Early-Stage High-Risk ERBB2 -Negative Breast Cancer
Isaacs, Claudine, Nanda, Rita, Yau, C, Chien, A. Jo, Hershman, Dawn L., Stringer-Reasor, Erica M., Wallace, Anne M., Clark, Amy S., Kennedy, Laura C., Sanford, Amy, Boughey, JC , Albain, Kathy S. , Pusztai, Lajos, Kalinsky, Kevin M., Beckwith, Heather, Williams, Nicole O., Han, Hyo S., Falkson, Carla, Arora, Mili, Pohlmann, Paula R., Rozenblit, Mariya, Marshall, Natalie, Chen, Yunn-Yi, McGuinness, Julia E., Howard, Frederick M., Chen, Nan, Khoury, Katia, Lancaster, Rachael, Douglas, Emily, Wei, Mei, Mainor, Candace, LeStage, Barbara, Matthews, Jeffrey B. , Perlmutter, J, Symmans, W. Fraser, Yee, Douglas, Hylton, Nola M., Veer, Laura van ‘t , Rugo, Hope S., Berry, Donald A., Esserman, Laura J., Isaacs, Claudine , Yau, Christina , Chien, A. Jo , Hershman, Dawn L. , Stringer-Reasor, Erica , Thomas, Alexandra , Vaklavas, Christos , Clark, Amy S. , Kennedy, Laura Carpin , Pusztai, Lajos , Kalinsky, Kevin M. , Beckwith, Heather , Han, Hyo S , Falkson, Carla I. , Arora, Mili, Elias, Anthony , Pohlmann, Paula R. , Rozenblit, Mariya , Trivedi, Meghna S. , McGuinness, Julia Elizabeth , Howard, F , Khoury, Katia , Yeung, Kay T. , Douglas, Emily, Mainor, Candace , LeStage, Barbara , Delson, Amy , Asare, Adam L. , Swigart, Lamorna Brown , Hirst, Gillian L. , Symmans, W. Fraser , Yee, Douglas , Veer, Laura J. van’t , Rugo, Hope S. , DeMichele, Angela , Berry, Donald A., Esserman, Laura J.

Mayo Clinic

JAMA Oncology | July 30, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1001/jamaoncol.2026.2576 | PMID 42530945 Get It

Importance Although adding immune checkpoint inhibitors to neoadjuvant chemotherapy improves outcomes in high-risk early-stage breast cancer, opportunities remain to further enhance response. Dual checkpoint blockade offers a potential strategy to further enhance efficacy. Objective To evaluate the combination of anti−programmed cell death 1 protein (PD-1) cemiplimab and anti−lymphocyte activation gene 3 (LAG-3) added to neoadjuvant therapy in ERBB2 -negative early-stage, high-risk breast cancer. Design, Setting, and Participants The I-SPY2 (Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging and Molecular Analysis 2) is an ongoing randomized clinical platform trial being conducted at multiple US clinical sites including patients with early-stage (II or III) ERBB2 -negative, high-risk breast cancer. Participants, continuously enrolled since 2010, were adaptively randomized from February 2, 2020, to December 9, 2021, to one of several experimental neoadjuvant therapies or control groups based on receptor subtypes defined by hormone receptor (HR), ERBB2 status, and MammaPrint (Agendia Inc) molecular risk, categorized as high (MP1) or ultrahigh (MP2). Data were analyzed from January 1, 2022, to August 5, 2025. Interventions Both groups received weekly paclitaxel for 12 weeks, then doxorubicin and cyclophosphamide followed by surgery; concomitant with paclitaxel, the intervention group also received 4 doses of cemiplimab and fianlimab (PCF) every 3 weeks. Main Outcomes and Measures Pathologic complete response (pCR). Treatments graduated when they achieved 85% bayesian probability of success in a subtype-specific phase 3 trial. Pathway-specific biomarkers were assessed for response prediction. Results A total of 78 participants (mean [SD] age, 47 [39-54] years) were randomized to the intervention group, with 350 participants (mean [SD] age, 48 [39-57] years) randomized to the historical control population. PCF graduated in all clinical signatures, with pCR rates vs control of 44% (95% CI, 34%-53%) vs 21% (95% CI, 17%-25%) in all ERBB2 , 53% (95% CI, 39%-67%) vs 29% (95% CI, 22%-36%) in triple-negative, and 36% (95% CI, 23%-49%) vs 14% (95% CI, 9%-19%) in HR-positive and ERBB2 -negative disease. Among the total participants, 16 (21%) experienced adrenal insufficiency, including hypophysitis (11% grade 3 or 4), mostly occurring after immunotherapy completion. PCF was found to be highly effective in the subset of patients with immune signature positive status (ImPrint positive). Conclusions and Relevance In this randomized clinical trial, the combination of PD-1 and anti−LAG-3 inhibition with standard NAC was effective in early-stage ERBB2 -negative breast cancer, particularly in patients displaying a positive ImPrint immune signature. These results warrant further definitive trials. Trial Registration ClinicalTrials.gov Identifier: NCT01042379